Mutational analysis of merkel cell carcinoma

Cancers

Volumn 6, Issue 4, 2014, Pages 2116-2136

  Erstad, Derek J ^a   Cusack, James C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Merkel cell carcinoma; Merkel cell polyomavirus; Mutational analysis; Oncogene; Prognostic algorithm; Tumor suppressor

Indexed keywords

CABOZANTINIB; CIXUTUMUMAB; EVEROLIMUS; IMATINIB; KIT PROTEIN; MICRORNA; NELFINAVIR; PAZOPANIB; PDGFRA PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN; PROTEIN KINASE B; PROTEIN P53; PROTEIN TYROSINE KINASE; RB1 PROTEIN; TEMSIROLIMUS; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VATALANIB;

ALGORITHM; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME ABERRATION; DRUG EFFICACY; ENZYME ACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; MERKEL CELL POLYOMAVIRUS; MERKEL CELL TUMOR; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RNA ANALYSIS; SIGNAL TRANSDUCTION;

EID: 84919762473     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers6042116     Document Type: Review

References (107)

1. Agelli, M.; Clegg, L.X.; Becker, J.C.; Rollison, D.E. The etiology and epidemiology of merkel cell carcinoma. Curr. Probl. Cancer 2010, 34, 14-37.
2. Lunder, E.J.; Stern, R.S. Merkel-cell carcinomas in patients treated with methoxsalen and ultraviolet a radiation. N. Engl. J. Med. 1998, 339, 1247-1248.
3. Howard, R.A.; Dores, G.M.; Curtis, R.E.; Anderson, W.F.; Travis, L.B. Merkel cell carcinoma and multiple primary cancers. Cancer Epidemiol. Biomarkers Prev. 2006, 15, 1545-1549.
4. Laude, H.C.; Jonchere, B.; Maubec, E.; Carlotti, A.; Marinho, E.; Couturaud, B.; Peter, M.; Sastre-Garau, X.; Avril, M.F.; Dupin, N., et al. Distinct merkel cell polyomavirus molecular features in tumour and non tumour specimens from patients with merkel cell carcinoma. PLoS Pathog. 2010, 6, e1001076.
5. Sahi, H.; Savola, S.; Sihto, H.; Koljonen, V.; Bohling, T.; Knuutila, S. Rb1 gene in merkel cell carcinoma: Hypermethylation in all tumors and concurrent heterozygous deletions in the polyomavirus-negative subgroup. APMIS 2014, doi:10.1111/apm.12274.
6. Popp, S.; Waltering, S.; Herbst, C.; Moll, I.; Boukamp, P. Uv-b-type mutations and chromosomal imbalances indicate common pathways for the development of merkel and skin squamous cell carcinomas. Int. J. Cancer 2002, 99, 352-360.
7. Albores-Saavedra, J.; Batich, K.; Chable-Montero, F.; Sagy, N.; Schwartz, A.M.; Henson, D.E. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: A population based study. J. Cutan. Pathol. 2010, 37, 20-27.
8. Andea, A.A.; Coit, D.G.; Amin, B.; Busam, K.J. Merkel cell carcinoma: Histologic features and prognosis. Cancer 2008, 113, 2549-2558.
9. Skelton, H.G.; Smith, K.J.; Hitchcock, C.L.; McCarthy, W.F.; Lupton, G.P.; Graham, J.H. Merkel cell carcinoma: Analysis of clinical, histologic, and immunohistologic features of 132 cases with relation to survival. J. Am. Acad. Dermatol. 1997, 37, 734-739.
10. Wong, H.H.; Wang, J. Merkel cell carcinoma. Arch. Pathol. Lab. Med. 2010, 134, 1711-1716.
11. Hanly, A.J.; Elgart, G.W.; Jorda, M.; Smith, J.; Nadji, M. Analysis of thyroid transcription factor-1 and cytokeratin 20 separates merkel cell carcinoma from small cell carcinoma of lung. J. Cutan. Pathol. 2000, 27, 118-120.
12. Tilling, T.; Moll, I. Which are the cells of origin in merkel cell carcinoma? J. Skin Cancer 2012, doi:10.1155/2012/680410.
13. Feng, H.; Shuda, M.; Chang, Y.; Moore, P.S. Clonal integration of a polyomavirus in human merkel cell carcinoma. Science 2008, 319, 1096-1100.
14. Coursaget, P.; Samimi, M.; Nicol, J.T.; Gardair, C.; Touze, A. Human merkel cell polyomavirus: Virological background and clinical implications. APMIS 2013, 121, 755-769.
15. Pastrana, D.V.; Tolstov, Y.L.; Becker, J.C.; Moore, P.S.; Chang, Y.; Buck, C.B. Quantitation of human seroresponsiveness to merkel cell polyomavirus. PLoS Pathog. 2009, 5, e1000578.
16. Heath, M.; Jaimes, N.; Lemos, B.; Mostaghimi, A.; Wang, L.C.; Penas, P.F.; Nghiem, P. Clinical characteristics of merkel cell carcinoma at diagnosis in 195 patients: The aeiou features. J. Am. Acad. Dermatol. 2008, 58, 375-381.
17. Tadmor, T.; Aviv, A.; Polliack, A. Merkel cell carcinoma, chronic lymphocytic leukemia and other lymphoproliferative disorders: An old bond with possible new viral ties. Ann. Oncol. 2011, 22, 250-256.
18. Harms, P.W.; Patel, R.M.; Verhaegen, M.E.; Giordano, T.J.; Nash, K.T.; Johnson, C.N.; Daignault, S.; Thomas, D.G.; Gudjonsson, J.E.; Elder, J.T., et al. Distinct gene expression profiles of viral-and nonviral-associated merkel cell carcinoma revealed by transcriptome analysis. J. Investig. Dermatol. 2013, 133, 936-945.
19. Kwun, H.J.; Shuda, M.; Feng, H.; Camacho, C.J.; Moore, P.S.; Chang, Y. Merkel cell polyomavirus small T antigen controls viral replication and oncoprotein expression by targeting the cellular ubiquitin ligase SCFFbw7. Cell Host Microbe 2013, 14, 125-135.
20. Shuda, M.; Kwun, H.J.; Feng, H.; Chang, Y.; Moore, P.S. Human merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4e-bp1 translation regulator. J. Clin. Investig. 2011, 121, 3623-3634.
21. Shuda, M.; Chang, Y.; Moore, P.S. Merkel cell polyomavirus-positive merkel cell carcinoma requires viral small T-antigen for cell proliferation. J. Investig. Dermatol. 2014, 134, 1479-1481.
22. Li, J.; Wang, X.; Diaz, J.; Tsang, S.H.; Buck, C.B.; You, J. Merkel cell polyomavirus large T antigen disrupts host genomic integrity and inhibits cellular proliferation. J. Virol. 2013, 87, 9173-9188.
23. Borchert, S.; Czech-Sioli, M.; Neumann, F.; Schmidt, C.; Wimmer, P.; Dobner, T.; Grundhoff, A.; Fischer, N. High-affinity Rb binding, p53 inhibition, subcellular localization, and transformation by wild-type or tumor-derived shortened merkel cell polyomavirus large T antigens. J. Virol. 2014, 88, 3144-3160.
24. Houben, R.; Adam, C.; Baeurle, A.; Hesbacher, S.; Grimm, J.; Angermeyer, S.; Henzel, K.; Hauser, S.; Elling, R.; Brocker, E.B., et al. An intact retinoblastoma protein-binding site in merkel cell polyomavirus large T antigen is required for promoting growth of merkel cell carcinoma cells. Int. J. Cancer 2012, 130, 847-856.
25. Shahzad, N.; Shuda, M.; Gheit, T.; Kwun, H.J.; Cornet, I.; Saidj, D.; Zannetti, C.; Hasan, U.; Chang, Y.; Moore, P.S., et al. The T antigen locus of merkel cell polyomavirus downregulates human toll-like receptor 9 expression. J. Virol. 2013, 87, 13009-13019.
26. Cheng, J.; Rozenblatt-Rosen, O.; Paulson, K.G.; Nghiem, P.; DeCaprio, J.A. Merkel cell polyomavirus large T antigen has growth-promoting and inhibitory activities. J. Virol. 2013, 87, 6118-6126.
27. Santamaria-Barria, J.A.; Boland, G.M.; Yeap, B.Y.; Nardi, V.; Dias-Santagata, D.; Cusack, J.C., Jr. Merkel cell carcinoma: 30-year experience from a single institution. Ann. Surg. Oncol. 2013, 20, 1365-1373.
28. Sihto, H.; Kukko, H.; Koljonen, V.; Sankila, R.; Bohling, T.; Joensuu, H. Clinical factors associated with merkel cell polyomavirus infection in merkel cell carcinoma. J. Natl. Cancer Inst. 2009, 101, 938-945.
29. Bhatia, K.; Goedert, J.J.; Modali, R.; Preiss, L.; Ayers, L.W. Immunological detection of viral large T antigen identifies a subset of merkel cell carcinoma tumors with higher viral abundance and better clinical outcome. Int. J. Cancer 2010, 127, 1493-1496.
30. Iyer, J.G.; Afanasiev, O.K.; McClurkan, C.; Paulson, K.; Nagase, K.; Jing, L.; Marshak, J.O.; Dong, L.; Carter, J.; Lai, I., et al. Merkel cell polyomavirus-specific cd8(+) and cd4(+) T-cell responses identified in merkel cell carcinomas and blood. Clin. Cancer Res. 2011, 17, 6671-6680.
31. Paulson, K.G.; Iyer, J.G.; Tegeder, A.R.; Thibodeau, R.; Schelter, J.; Koba, S.; Schrama, D.; Simonson, W.T.; Lemos, B.D.; Byrd, D.R., et al. Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral cd8+ lymphocyte invasion as an independent predictor of survival. J. Clin. Oncol. 2011, 29, 1539-1546.
32. Higaki-Mori, H.; Kuwamoto, S.; Iwasaki, T.; Kato, M.; Murakami, I.; Nagata, K.; Sano, H.; Horie, Y.; Yoshida, Y.; Yamamoto, O., et al. Association of merkel cell polyomavirus infection with clinicopathological differences in merkel cell carcinoma. Hum. Pathol. 2012, 43, 2282-2291.
33. Triozzi, P.L.; Fernandez, A.P. The role of the immune response in merkel cell carcinoma. Cancers 2013, 5, 234-254.
34. Chompret, A.; Kannengiesser, C.; Barrois, M.; Terrier, P.; Dahan, P.; Tursz, T.; Lenoir, G.M.; Bressac-De Paillerets, B. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology 2004, 126, 318-321.
35. Swick, B.L.; Ravdel, L.; Fitzpatrick, J.E.; Robinson, W.A. Platelet-derived growth factor receptor alpha mutational status and immunohistochemical expression in merkel cell carcinoma: Implications for treatment with imatinib mesylate. J. Cutan. Pathol. 2008, 35, 197-202.
36. Andea, A.A.; Patel, R.; Ponnazhagan, S.; Kumar, S.; DeVilliers, P.; Jhala, D.; Eltoum, I.E.; Siegal, G.P. Merkel cell carcinoma: Correlation of kit expression with survival and evaluation of kit gene mutational status. Hum. Pathol. 2010, 41, 1405-1412.
37. Swick, B.L.; Srikantha, R.; Messingham, K.N. Specific analysis of KIT and PDGFR-alpha expression and mutational status in merkel cell carcinoma. J. Cutan. Pathol. 2013, 40, 623-630.
38. Kartha, R.V.; Sundram, U.N. Silent mutations in kit and pdgfra and coexpression of receptors with SCF and PDGFA in merkel cell carcinoma: Implications for tyrosine kinase-based tumorigenesis. Mod. Pathol. 2008, 21, 96-104.
39. Nardi, V.; Song, Y.; Santamaria-Barria, J.A.; Cosper, A.K.; Lam, Q.; Faber, A.C.; Boland, G.M.; Yeap, B.Y.; Bergethon, K.; Scialabba, V.L., et al. Activation of PI3K signaling in merkel cell carcinoma. Clin. Cancer Res. 2012, 18, 1227-1236.
40. Karakas, B.; Bachman, K.E.; Park, B.H. Mutation of the PIK3CA oncogene in human cancers. Br. J. Cancer 2006, 94, 455-459.
41. Lopez-Knowles, E.; Hernandez, S.; Malats, N.; Kogevinas, M.; Lloreta, J.; Carrato, A.; Tardon, A.; Serra, C.; Real, F.X. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res. 2006, 66, 7401-7404.
42. Hafner, C.; Hartmann, A.; Vogt, T. FGFR3 mutations in epidermal nevi and seborrheic keratoses: Lessons from urothelium and skin. J. Investig. Dermatol. 2007, 127, 1572-1573.
43. Hafner, C.; Houben, R.; Baeurle, A.; Ritter, C.; Schrama, D.; Landthaler, M.; Becker, J.C. Activation of the PI3K/AKT pathway in merkel cell carcinoma. PLoS One 2012, 7, e31255.
44. Van Gele, M.; Leonard, J.H.; van Roy, N.; Cook, A.L.; de Paepe, A.; Speleman, F. Frequent allelic loss at 10q23 but low incidence of pten mutations in merkel cell carcinoma. Int. J. Cancer 2001, 92, 409-413.
45. Samlowski, W.E.; Moon, J.; Tuthill, R.J.; Heinrich, M.C.; Balzer-Haas, N.S.; Merl, S.A.; DeConti, R.C.; Thompson, J.A.; Witter, M.T.; Flaherty, L.E., et al. A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A southwest oncology group study (s0331). Am. J. Clin. Oncol. 2010, 33, 495-499.
46. National Cancer Institute. Prospective randomized phase II trial of pazopanib (NSC # 737754) versus placebo in patients with progressive carcinoid tumors. Available online: http://clinicaltrials.gov?show/nct01841736 (accessed on 1 June 2014).
47. Dana-farber Cancer Institute; Exelixis. Cabozantinib in recurrent/metastatic Merkel cell carcinoma. Available online: http://clinicaltrials.gov/show/nct02036476 (accessed on 1 June 2014).
48. National Cancer Institute. Nelfinavir in treating patients with metastatic, refractory, or recurrent solid tumors. Available online: http://clinicaltrials.gov/show/nct00436735 (accessed on 1 June 2014).
49. National Cancer Institute. Phase I study of anti-igf-1r monoclonal antibody, Imc-a12, and mtor inhibitor, everolimus, in advanced low to intermediate grade neuroendocrine carcinoma. Available online: http://clinicaltrials.gov/show/nct01204476 (accessed on 1 June 2014).
50. National Cancer Institute. A Phase I trial of the mtor inhibitor Rad001 in combination with VEGF receptor tyrosine kinase inhibitor ptk787/zk 222584 in patients with advanced solid tumors. Available online: http://clinicaltrials.GOV/show/nct00655655 (accessed on 1 June 2014).
51. Pfizer; University of Southern California. Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. Available online: http://clinicaltrials.gov/show/nct01155258 (accessed on 1 June 2014).
52. National Cancer Institute. A phase II trial of sti-571/imatinib (Gleevec®) (Nsc-716051) in neuroendocrine carcinoma of the skin (Merkel Cell Carcinoma). Available online: http://clinicaltrials.gov/show/nct00068783 (s).
53. Carson, H.J.; Lueck, N.E.; Horten, B.C. Comparison of mutant and wild-type p53 proteins in merkel cell carcinoma. Clin. Diagn. Lab. Immunol. 2000, 7, 326.
54. Lill, C.; Schneider, S.; Item, C.B.; Loewe, R.; Houben, R.; Halbauer, D.; Heiduschka, G.; Brunner, M.; Thurnher, D. P53 mutation is a rare event in merkel cell carcinoma of the head and neck. Eur. Arch. Otorhinolaryngol. 2011, 268, 1639-1646.
55. Waltari, M.; Sihto, H.; Kukko, H.; Koljonen, V.; Sankila, R.; Bohling, T.; Joensuu, H. Association of merkel cell polyomavirus infection with tumor p53, KIT, stem cell factor, PDGFR-alpha and survival in merkel cell carcinoma. Int. J. Cancer 2011, 129, 619-628.
56. Lassacher, A.; Heitzer, E.; Kerl, H.; Wolf, P. p14ARF hypermethylation is common but INK4a-ARF locus or p53 mutations are rare in merkel cell carcinoma. J. Investig. Dermatol. 2008, 128, 1788-1796.
57. Van Gele, M.; Kaghad, M.; Leonard, J.H.; van Roy, N.; Naeyaert, J.M.; Geerts, M.L.; van Belle, S.; Cocquyt, V.; Bridge, J.; Sciot, R., et al. Mutation analysis of p73 and tp53 in merkel cell carcinoma. Br. J. Cancer 2000, 82, 823-826.
58. Harris, C.C.; Hollstein, M. Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med. 1993, 329, 1318-1327.
59. Momand, J.; Zambetti, G.P.; Olson, D.C.; George, D.; Levine, A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69, 1237-1245.
60. Oliner, J.D.; Kinzler, K.W.; Meltzer, P.S.; George, D.L.; Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992, 358, 80-83.
61. Houben, R.; Dreher, C.; Angermeyer, S.; Borst, A.; Utikal, J.; Haferkamp, S.; Peitsch, W.K.; Schrama, D.; Hesbacher, S. Mechanisms of p53 restriction in merkel cell carcinoma cells are independent of the merkel cell polyoma virus T antigens. J. Investig. Dermatol. 2013, 133, 2453-2460.
62. Leonard, J.H.; Hayard, N. Loss of heterozygosity of chromosome 13 in merkel cell carcinoma. Genes Chromosomes Cancer 1997, 20, 93-97.
63. Cimino, P.J.; Robirds, D.H.; Tripp, S.R.; Pfeifer, J.D.; Abel, H.J.; Duncavage, E.J. Retinoblastoma gene mutations detected by whole exome sequencing of merkel cell carcinoma. Mod. Pathol. 2014, 27, 1073-1087.
64. Larramendy, M.L.; Koljonen, V.; Bohling, T.; Tukiainen, E.; Knuutila, S. Recurrent DNA copy number changes revealed by comparative genomic hybridization in primary merkel cell carcinomas. Mod. Pathol. 2004, 17, 561-567.
65. Harle, M.; Arens, N.; Moll, I.; Back, W.; Schulz, T.; Scherthan, H. Comparative genomic hybridization (cgh) discloses chromosomal and subchromosomal copy number changes in merkel cell carcinomas. J. Cutan. Pathol. 1996, 23, 391-397.
66. Van Gele, M.; Leonard, J.H.; van Roy, N.; van Limbergen, H.; van Belle, S.; Cocquyt, V.; Salwen, H.; de Paepe, A.; Speleman, F. Combined karyotyping, CGH and M-FISH analysis allows detailed characterization of unidentified chromosomal rearrangements in merkel cell carcinoma. Int. J. Cancer 2002, 101, 137-145.
67. Paulson, K.G.; Lemos, B.D.; Feng, B.; Jaimes, N.; Penas, P.F.; Bi, X.; Maher, E.; Cohen, L.; Leonard, J.H.; Granter, S.R., et al. Array-CGH reveals recurrent genomic changes in merkel cell carcinoma including amplification of L-Myc. J. Investig. Dermatol. 2009, 129, 1547-1555.
68. Vortmeyer, A.O.; Merino, M.J.; Boni, R.; Liotta, L.A.; Cavazzana, A.; Zhuang, Z. Genetic changes associated with primary merkel cell carcinoma. Am. J. Clin. Pathol. 1998, 109, 565-570.
69. Harnett, P.R.; Kearsley, J.H.; Hayward, N.K.; Dracopoli, N.C.; Kefford, R.F. Loss of allelic heterozygosity on distal chromosome 1p in merkel cell carcinoma. A marker of neural crest origins? Cancer Genet. Cytogenet. 1991, 54, 109-113.
70. Van Gele, M.; Speleman, F.; Vandesompele, J.; van Roy, N.; Leonard, J.H. Characteristic pattern of chromosomal gains and losses in merkel cell carcinoma detected by comparative genomic hybridization. Cancer Res. 1998, 58, 1503-1508.
71. Leonard, J.H.; Williams, G.; Walters, M.K.; Nancarrow, D.J.; Rabbitts, P.H. Deletion mapping of the short arm of chromosome 3 in merkel cell carcinoma. Genes Chromosomes Cancer 1996, 15, 102-107.
72. Gancberg, D.; Feoli, F.; Hamels, J.; de Saint-Aubain, N.; Andre, J.; Rouas, G.; Verhest, A.; Larsimont, D. Trisomy 6 in merkel cell carcinoma: A recurrent chromosomal aberration. Histopathology 2000, 37, 445-451.
73. Vasuri, F.; Magrini, E.; Foschini, M.P.; Eusebi, V. Trisomy of chromosome 6 in merkel cell carcinoma within lymph nodes. Virchows Arch. 2008, 452, 559-563.
74. Suciu, V.; Botan, E.; Valent, A.; Chami, L.; Spatz, A.; Vielh, P. The potential contribution of fluorescent in situ hybridization analysis to the cytopathological diagnosis of merkel cell carcinoma. Cytopathology 2008, 19, 48-51.
75. Sandbrink, F.; Muller, L.; Fiebig, H.H.; Kovacs, G. Short communication: Deletion 7q, trisomy 6 and 11 in a case of merkel-cell carcinoma. Cancer Genet. Cytogenet. 1988, 33, 305-309.
76. Shabtai, F.; Sternberg, A.; Klar, D.; Reiss, R.; Halbrecht, I. Involvement of chromosome 22 in a merkel cell carcinoma in a patient with a previous meningioma. Cancer Genet. Cytogenet. 1989, 38, 43-48.
77. Xie, H.; Lee, L.; Caramuta, S.; Hoog, A.; Browaldh, N.; Bjornhagen, V.; Larsson, C.; Lui, W.O. Microrna expression patterns related to merkel cell polyomavirus infection in human merkel cell carcinoma. J. Investig. Dermatol. 2014, 134, 507-517.
78. Boll, K.; Reiche, K.; Kasack, K.; Morbt, N.; Kretzschmar, A.K.; Tomm, J.M.; Verhaegh, G.; Schalken, J.; von Bergen, M.; Horn, F., et al. Mir-130a, mir-203 and mir-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene 2013, 32, 277-285.
79. Chiang, Y.; Song, Y.; Wang, Z.; Chen, Y.; Yue, Z.; Xu, H.; Xing, C.; Liu, Z. Aberrant expression of mir-203 and its clinical significance in gastric and colorectal cancers. J. Gastrointest. Surg. 2011, 15, 63-70.
80. Jin, J.; Deng, J.; Wang, F.; Xia, X.; Qiu, T.; Lu, W.; Li, X.; Zhang, H.; Gu, X.; Liu, Y., et al. The expression and function of microrna-203 in lung cancer. Tumour Biol. 2013, 34, 349-357.
81. Diao, Y.; Guo, X.; Jiang, L.; Wang, G.; Zhang, C.; Wan, J.; Jin, Y.; Wu, Z. Mir-203, a tumor suppressor frequently down-regulated by promoter hypermethylation in rhabdomyosarcoma. J. Biol. Chem. 2014, 289, 529-539.
82. Knapp, C.F.; Sayegh, Z.; Schell, M.J.; Rawal, B.; Ochoa, T.; Sondak, V.K.; Messina, J.L. Expression of cxcr4, e-cadherin, bcl-2, and survivin in merkel cell carcinoma: An immunohistochemical study using a tissue microarray. Am. J. Dermatopathol. 2012, 34, 592-596.
83. Dresang, L.R.; Guastafierro, A.; Arora, R.; Normolle, D.; Chang, Y.; Moore, P.S. Response of merkel cell polyomavirus-positive merkel cell carcinoma xenografts to a survivin inhibitor. PLoS One 2013, 8, e80543.
84. Ning, M.S.; Kim, A.S.; Prasad, N.; Levy, S.E.; Zhang, H.; Andl, T. Characterization of the merkel cell carcinoma mirnome. J. Skin Cancer 2014, doi:10.1155/2014/289548.
85. Banzhaf-Strathmann, J.; Edbauer, D. Good guy or bad guy: The opposing roles of microrna 125b in cancer. Cell Commun. Signal. 2014, doi:10.1186/1478-811X-12-30.
86. Segura, M.F.; Hanniford, D.; Menendez, S.; Reavie, L.; Zou, X.; Alvarez-Diaz, S.; Zakrzewski, J.; Blochin, E.; Rose, A.; Bogunovic, D., et al. Aberrant mir-182 expression promotes melanoma metastasis by repressing foxo3 and microphthalmia-associated transcription factor. Proc. Natl. Acad. Sci. USA 2009, 106, 1814-1819.
87. Swick, B.L.; Ravdel, L.; Fitzpatrick, J.E.; Robinson, W.A. Merkel cell carcinoma: Evaluation of kit (cd117) expression and failure to demonstrate activating mutations in the c-kit proto-oncogene—Implications for treatment with imatinib mesylate. J. Cutan. Pathol. 2007, 34, 324-329.
88. Liu, S.; Daa, T.; Kashima, K.; Kondoh, Y.; Yokoyama, S. The wnt-signaling pathway is not implicated in tumorigenesis of merkel cell carcinoma. J. Cutan. Pathol. 2007, 34, 22-26.
89. Lill, C.; Schneider, S.; Ghanim, B.; Brunner, M.; Heiduschka, G.; Loewe, R.; Thurnher, D. Expression of beta-catenin and cyclin d1 in merkel cell carcinomas of the head and neck. Wien. Klin. Wochenschr. 2013, 125, 501-507.
90. Worda, M.; Sreevidya, C.S.; Ananthaswamy, H.N.; Cerroni, L.; Kerl, H.; Wolf, P. T1796a braf mutation is absent in merkel cell carcinoma. Br. J. Dermatol. 2005, 153, 229-232.
91. Houben, R.; Michel, B.; Vetter-Kauczok, C.S.; Pfohler, C.; Laetsch, B.; Wolter, M.D.; Leonard, J.H.; Trefzer, U.; Ugurel, S.; Schrama, D., et al. Absence of classical map kinase pathway signalling in merkel cell carcinoma. J. Investig. Dermatol. 2006, 126, 1135-1142.
92. Filtenborg-Barnkob, B.E.; Bzorek, M. Expression of anaplastic lymphoma kinase in merkel cell carcinomas. Hum. Pathol. 2013, 44, 1656-1664.
93. Nagahama, J.; Daa, T.; Yada, N.; Kashima, K.; Fujiwara, S.; Saikawa, T.; Yokoyama, S. Tyrosine kinase receptor ron and its ligand msp in merkel cell carcinoma. Pathol. Res. Pract. 2011, 207, 463-467.
94. Panelos, J.; Batistatou, A.; Paglierani, M.; Zioga, A.; Maio, V.; Santi, R.; Pimpinelli, N.; de Giorgi, V.; Santucci, M.; Massi, D., et al. Expression of notch-1 and alteration of the e-cadherin/beta-catenin cell adhesion complex are observed in primary cutaneous neuroendocrine carcinoma (merkel cell carcinoma). Mod. Pathol. 2009, 22, 959-968.
95. Sihto, H.; Kukko, H.; Koljonen, V.; Sankila, R.; Bohling, T.; Joensuu, H. Merkel cell polyomavirus infection, large T antigen, retinoblastoma protein and outcome in merkel cell carcinoma. Clin. Cancer Res. 2011, 17, 4806-4813.
96. Paulson, K.G.; Carter, J.J.; Johnson, L.G.; Cahill, K.W.; Iyer, J.G.; Schrama, D.; Becker, J.C.; Madeleine, M.M.; Nghiem, P.; Galloway, D.A., et al. Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. Cancer Res. 2010, 70, 8388-8397.
97. Touze, A.; le Bidre, E.; Laude, H.; Fleury, M.J.; Cazal, R.; Arnold, F.; Carlotti, A.; Maubec, E.; Aubin, F.; Avril, M.F., et al. High levels of antibodies against merkel cell polyomavirus identify a subset of patients with merkel cell carcinoma with better clinical outcome. J. Clin. Oncol. 2011, 29, 1612-1619.
98. Asioli, S.; Righi, A.; de Biase, D.; Morandi, L.; Caliendo, V.; Picciotto, F.; Macripo, G.; Maletta, F.; di Cantogno, L.V.; Chiusa, L., et al. Expression of p63 is the sole independent marker of aggressiveness in localised (stage I-II) merkel cell carcinomas. Mod. Pathol. 2011, 24, 1451-1461.
99. Stetsenko, G.Y.; Malekirad, J.; Paulson, K.G.; Iyer, J.G.; Thibodeau, R.M.; Nagase, K.; Schmidt, M.; Storer, B.E.; Argenyi, Z.B.; Nghiem, P., et al. P63 expression in merkel cell carcinoma predicts poorer survival yet may have limited clinical utility. Am. J. Clin. Pathol. 2013, 140, 838-844.
100. Lim, C.S.; Whalley, D.; Haydu, L.E.; Murali, R.; Tippett, J.; Thompson, J.F.; Hruby, G.; Scolyer, R.A. Increasing tumor thickness is associated with recurrence and poorer survival in patients with merkel cell carcinoma. Ann. Surg. Oncol. 2012, 19, 3325-3334.
101. Llombart, B.; Monteagudo, C.; Lopez-Guerrero, J.A.; Carda, C.; Jorda, E.; Sanmartin, O.; Almenar, S.; Molina, I.; Martin, J.M.; Llombart-Bosch, A., et al. Clinicopathological and immunohistochemical analysis of 20 cases of merkel cell carcinoma in search of prognostic markers. Histopathology 2005, 46, 622-634.
102. Kurzen, H.; Kaul, S.; Egner, U.; Deichmann, M.; Hartschuh, W. Expression of muc 1 and ep-cam in merkel cell carcinomas: Implications for immunotherapy. Arch. Dermatol. Res. 2003, 295, 146-154.
103. Koljonen, V.; Jahkola, T.; Tukiainen, E.; Granroth, G.; Haglund, C.; Bohling, T. Tenascin-c in primary merkel cell carcinoma. J. Clin. Pathol. 2005, 58, 297-300.
104. Brunner, M.; Thurnher, D.; Pammer, J.; Heiduschka, G.; Petzelbauer, P.; Schmid, C.; Schneider, S.; Erovic, B.M. Expression of hedgehog signaling molecules in merkel cell carcinoma. Head Neck 2010, 32, 333-340.
105. Fernandez-Figueras, M.T.; Puig, L.; Musulen, E.; Gilaberte, M.; Lerma, E.; Serrano, S.; Ferrandiz, C.; Ariza, A. Expression profiles associated with aggressive behavior in merkel cell carcinoma. Mod. Pathol. 2007, 20, 90-101.
106. Lill, C.; Schneider, S.; Pammer, J.; Loewe, R.; Gedlicka, W.; Houben, R.; Heiduschka, G.; Brunner, M.; Thurnher, D. Significant correlation of peptidyl-prolyl isomerase overexpression in merkel cell carcinoma with overall survival of patients. Head Neck 2011, 33, 1294-1300.
107. Koljonen, V.; Haglund, C.; Tukiainen, E.; Bohling, T. Neuroendocrine differentiation in primary merkel cell carcinoma—Possible prognostic significance. Anticancer Res. 2005, 25, 853-858.